US2006211058A1PendingUtilityA1

Diagnosis and treatment of malignant neoplasms

54
Assignee: WANDS JACK RPriority: Nov 8, 1999Filed: Mar 15, 2006Published: Sep 21, 2006
Est. expiryNov 8, 2019(expired)· nominal 20-yr term from priority
Inventors:Jack R. WandsSuzanne De La MonteNedim InceRolf I. Carlson
C12Y 114/11016A61K 31/4412G01N 2500/10C07K 16/40C12N 2799/027A61P 43/00C12N 9/0071A61K 31/00C07K 14/47G01N 2500/00C12Q 1/26A61K 2039/505A61P 35/00C12N 2310/111C12N 2310/315C12N 15/1137G01N 33/5758G01N 33/575
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.

Claims

exact text as granted — not AI-modified
1 . A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily fluid from said mammal with an antibody or fragment thereof which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein an increase in antigen-antibody complex indicates an increase in HAAH level compared to a normal noncancerous control, said increase being indicative of a malignant neoplasm and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.  
     
     
         2 . The method of  claim 1 , wherein said neoplasm is derived from endodermal tissue.  
     
     
         3 . The method of  claim 1 , wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.  
     
     
         4 . The method of  claim 1 , wherein said neoplasm is a cancer of the central nervous system (CNS).  
     
     
         5 . The method of  claim 1 , wherein said bodily fluid is selected from the group consisting of a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid.  
     
     
         6 . The method of  claim 5 , wherein said bodily fluid is serum.  
     
     
         7 . A method for prognosis of a malignant neoplasm of a mammal, comprising 
 (a) contacting a bodily fluid from said mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex;    (b) quantitating the amount of complex to determine the level of HAAH in said fluid; and    (c) comparing the level of HAAH in said fluid with a normal noncancerous control level of HAAH, wherein increasing levels of HAAH over time indicates an adverse prognosis, and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.    
     
     
         8 . The method of  claim 1  or  7 , wherein said antibody is a single chain Fv molecule.  
     
     
         9 . The method of  claim 8 , wherein said molecule is obtained from an antibody produced by hybridoma ATCC designation PTA 3386.  
     
     
         10 . The method of  claim 1  or  7 , wherein the antigen-antibody complex is detected by a label selected from consisting of an enzymatic label, a fluorescent label, a chemiluminescent label, a radioactive label, and a dye label.  
     
     
         11 . The method of  claim 1 , wherein said neoplasm is a hepatocellular carcinoma.  
     
     
         12 . The method of  claim 1 , wherein said neoplasm is a cholangiocarcinoma.  
     
     
         13 . The method of  claim 1 , wherein said neoplasm is a glioblastoma.  
     
     
         14 . The method of  claim 1 , wherein said neoplasm is a neuroblastoma.  
     
     
         15 . The method of  claim 1 , wherein said neoplasm is a pancreatic cancer.  
     
     
         16 . The method of  claim 1 , wherein said antibody comprises a first HAAH-specific antibody and a second HAAH-specific antibody.  
     
     
         17 . The method of  claim 1 , wherein said tumor is a neuroectodermal tumor.  
     
     
         18 . A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily tissue from said mammal with an antibody or fragment thereof which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex, wherein an increase in antigen-antibody complex indicates an increase in HAAH level compared to a normal noncancerous control, said increase being indicative of a malignant neoplasm and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.  
     
     
         19 . The method of  claim 18 , wherein said neoplasm is derived from endodermal tissue.  
     
     
         20 . The method of  claim 18 , wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.  
     
     
         21 . The method of  claim 18 , wherein said neoplasm is a cancer of the central nervous system (CNS).  
     
     
         22 . The method of  claim 18 , wherein said bodily tissue is a solid tumor biopsy.  
     
     
         23 . The method of  claim 18 , wherein said tissue is a histopathological tissue.  
     
     
         24 . A method for prognosis of a malignant neoplasm of a mammal, comprising 
 (a) contacting a bodily tissue from said mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex;    (b) quantitating the amount of complex to determine the level of HAAH in said fluid; and    (c) comparing the level of HAAH in said tissue with a normal noncancerous control level of HAAH, wherein increasing levels of HAAH over time indicates an adverse prognosis, and wherein said antibody is a monoclonal antibody produced by hybridoma ATCC designation 3386.    
     
     
         25 . The method of  claim 18  or  24 , wherein said antibody is a single chain Fv molecule.  
     
     
         26 . The method of  claim 25 , wherein said molecule is obtained from an antibody produced by hybridoma ATCC designation PTA 3386.  
     
     
         27 . The method of  claim 18  or  24 , wherein the antigen-antibody complex is detected by a label selected from consisting of an enzymatic label, a fluorescent label, a chemiluminescent label, a radioactive label, and a dye label.  
     
     
         28 . The method of  claim 18 , wherein said neoplasm is a hepatocellular carcinoma.  
     
     
         29 . The method of  claim 18 , wherein said neoplasm is a cholangiocarcinoma.  
     
     
         30 . The method of  claim 18 , wherein said neoplasm is a glioblastoma.  
     
     
         31 . The method of  claim 18 , wherein said neoplasm is a neuroblastoma.  
     
     
         32 . The method of  claim 18 , wherein said neoplasm is a pancreatic cancer.  
     
     
         33 . The method of  claim 18 , wherein said antibody comprises a first HAAH-specific antibody and a second HAAH-specific antibody.  
     
     
         34 . The method of  claim 18 , wherein said tumor is a neuroectodermal tumor.

Join the waitlist — get patent alerts

Track US2006211058A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.